The tech scene in Southern California is thriving with companies across various specialties fueling continued growth and innovation. From a direct-to-consumer beverage solution to a mobile commerce app, learn what’s in the works for these venture-backed tech companies.
Top LA Tech Funding Rounds, April 2024
- TORL Biotherapeutics
- Flip
- FloQast
- Nominal
- Full Glass Wine Co.
#5. $14 million, April 4
The direct-to-consumer wine brand acquisition firm pulled in $14 million in Series A funding led by Shea Ventures. Full Glass Wine Co. recently expanded its business by acquiring subscription-based wine service Bright Cellars. The money will help the company fuel its growth through acquisitions and product development.
#4. $27.5 million, April 22
Nominal, a data analysis company serving industrial engineering teams, recently emerged from stealth with rounds of seed and Series A funding, led by Lux Capital and General Catalyst, respectively. The company will roll out its solution designed to facilitate and expedite the process of analyzing and reviewing test data for engineering teams. It will also invest in growing its team and enhancing its security capabilities.
#3. $100 million, April 10
Backed by a round of Series E funding led by ICONIQ Growth, finance and accounting company FloQast plans to fuel its continued global expansion. The company will also invest in developing new solutions and incorporating artificial intelligence capabilities into its platform.
#2. $144 million, April 2
Social commerce platform Flip plans to relaunch its market platform for brands using AppLovin’s AXON technology. Flip secured a round of Series C funding including a sizable investment from Applovin. Its platform’s relaunch will enable Flip brands to leverage an AI advertising engine via AXON Connect to reach more customers in measurable ways.
#1. $158 million, April 10
Deep Track Capital led an oversubscribed round of Series B-2 funding for TORL, a biotech platform developing antibody-based immunotherapies for patients with cancer. The company’s new capital will help it continue the clinical development of its antibody-drug conjugate for certain tumors. It will also help fund ongoing studies for several other therapeutic programs.
